Printer Friendly

PharmaPoint: Type 2 Diabetes - Current and Future Players.

NEW YORK, Nov. 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Type 2 Diabetes - Current and Future Players

http://www.reportlinker.com/p01889423/PharmaPoint-Type-2-Diabetes---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Type 2 Diabetes - Current and Future Players

Summary GlobalData has released its pharma report, "PharmaPoint: Type 2 Diabetes - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Type 2 Diabetes Market. The report identifies and analyses the key companies shaping and driving the global Type 2 Diabetes market. The report provides insight into the competitive Type 2 Diabetes landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope - Investigation of current and future market competition for Type 2 Diabetes - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the Type 2 Diabetes sector through market impact analysis, future market scenario and company analysis

Reasons to buy - Gain a high level view of the trends shaping and driving the Type 2 Diabetes Market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global Type 2 Diabetes market landscape? Identify, understand and capitalize

Table of Contents 1 Table of Contents 7 1.1 List of Tables 9 1.2 List of Figures 10 2 Introduction 11 2.1 Catalyst 11 2.2 Related Reports 12 3 Market Outlook 15 3.1 Global Markets 15 3.1.1 Forecast 15 3.1.2 Drivers and Barriers - Global Issues 21 4 Current and Future Players 23 4.1 Overview 23 4.2 Trends in Corporate Strategy 26 4.3 Company Profiles 27 4.3.1 Eli Lilly 27 4.3.2 Bristol-Myers Squibb 30 4.3.3 Novo Nordisk 33 4.3.4 Sanofi 36 4.3.5 GlaxoSmithKline 39 4.3.6 AstraZeneca 41 4.3.7 Merck & Co 43 4.3.8 Boehringer Ingelheim 45 4.3.9 Takeda 47 4.3.10 Roche 49 4.3.11 Pfizer 51 4.3.12 Johnson & Johnson 53 5 Appendix 55 5.1 Bibliography 55 5.2 Abbreviations 57 5.3 Methodology 60 5.4 Forecasting Methodology 60 5.4.1 Diagnosed Type 2 Patients 60 5.4.2 Percent Drug-Treated Patients 61 5.4.3 Drugs Included in Each Therapeutic Class 61 5.4.4 Launch and Patent Expiry Dates 62 5.4.5 General Pricing Assumptions 63 5.4.6 Individual Drug Assumptions 64 5.4.7 Generic Erosion 73 5.4.8 Pricing of Pipeline Agents 73 5.5 Physicians and Specialists Included in this Study 75 5.6 About the Authors 77 5.6.1 Analyst II - CVMD 77 5.6.2 Therapy Director - CVMD and Infectious Disease 77 5.6.3 Global Head of Healthcare 78 5.7 About GlobalData 79 5.8 Disclaimer 79

List of Tables Table 1: Global Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 18 Table 2: Type 2 Diabetes Market - Drivers and Barriers, 2012 21 Table 3: Key Companies in the Type 2 Diabetes Market, 2012 24 Table 4: Other Companies in the Type 2 Diabetes Market, 2012 25 Table 5: Eli Lilly's Type 2 Diabetes Portfolio Assessment, 2013 29 Table 6: Eli Lilly SWOT Analysis, 2012 30 Table 7: Bristol-Myers Squibb's Type 2 Diabetes Portfolio Assessment, 2013 32 Table 8: Bristol-Myers Squibb SWOT Analysis, 2012 33 Table 9: Novo Nordisk's Type 2 Diabetes Portfolio Assessment, 2013 35 Table 10: Novo Nordisk SWOT Analysis, 2012 36 Table 11: Sanofi's Type 2 Diabetes Portfolio Assessment, 2013 38 Table 12: Sanofi SWOT Analysis, 2012 38 Table 13: GSK's Type 2 Diabetes Portfolio Assessment, 2013 40 Table 14: GSK SWOT Analysis, 2012 40 Table 15: AstraZeneca's Type 2 Diabetes Portfolio Assessment, 2013 42 Table 16: AstraZeneca SWOT Analysis, 2012 42 Table 17: Merck's Type 2 Diabetes Portfolio Assessment, 2013 44 Table 18: Merck SWOT Analysis, 2012 44 Table 19: Boehringer Ingelheim's Type 2 Diabetes Portfolio Assessment, 2013 46 Table 20: Boehringer Ingelheim SWOT Analysis, 2012 46 Table 21: Takeda's Type 2 Diabetes Portfolio Assessment, 2013 48 Table 22: Takeda SWOT Analysis, 2012 49 Table 23: Roche's Type 2 Diabetes Portfolio Assessment, 2013 50 Table 24: Roche SWOT Analysis, 2012 50 Table 25: Pfizer's Type 2 Diabetes Portfolio Assessment, 2013 52 Table 26: Pfizer SWOT Analysis, 2012 52 Table 27: J&J's Type 2 Diabetes Portfolio Assessment, 2013 53 Table 28: J&J SWOT Analysis, 2012 54 Table 29: Key Launch Dates 62 Table 30: Key Patent Expiries 62 Table 31: Number of High-Prescribing Physicians Surveyed 76

List of Figures Figure 1: Global Sales for Type 2 Diabetes by Region, 2011-2022 20 Figure 2: Company Portfolio Gap Analysis in Type 2 Diabetes, 2012-2022 25

Companies Mentioned Eli Lilly Bristol-Myers Squibb Novo Nordisk Sanofi GlaxoSmithKline AstraZeneca Merck & Co Boehringer Ingelheim Takeda Roche Pfizer Johnson & Johnson

To order this report: PharmaPoint: Type 2 Diabetes - Current and Future Players http://www.reportlinker.com/p01889423/PharmaPoint-Type-2-Diabetes---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker
COPYRIGHT 2013 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 28, 2013
Words:1123
Previous Article:Belgium's Land Based Casino, Starbet, is Set to Expand its Land Operations into the Online and Mobile Mediums Partnering with Leading Sports Betting...
Next Article:Analysis of the Global Web Conferencing Market.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters